Omalizumab improves efficacy of oral immunotherapy for multiple food allergies

Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show.

Different types of foods that can cause allergic reactions. Image credit: David Castor/Wikipedia (CC BY-SA 3.0)

After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT.

Approximately 30 percent of people with food allergy are allergic to multiple foods. Results from the Phase 2 study build on previous work suggesting that omalizumab, an injectable antibody drug approved to treat moderate to severe allergic asthma, can improve the safety and efficacy of OIT for allergies to a single food.

Omalizumab blocks the activity of IgE, an immune system molecule central to the allergic response.

Researchers at the Stanford University School of Medicine enrolled 48 participants aged 4 to 15 years with confirmed allergy to multiple foods, including milk, egg, wheat, soy, sesame seeds, peanut or tree nuts.

Participants were randomly assigned to receive omalizumab or placebo injections for the first 16 weeks of the study.

At week eight, all participants began daily OIT, an investigational treatment that involves eating small, gradually increasing doses of an allergenic food. They continued OIT until week 36 of the study, at which point they underwent an oral food challenge.

Among the 36 children who received omalizumab, 30 (83 percent) were able to eat at least two grams of two or more foods to which they were allergic, compared with only 4 out of 12 children (33 percent) who received placebo.

Those who received omalizumab also experienced fewer adverse events from OIT during weeks 8 to 16 of the study.

The findings suggest the potential benefits of using omalizumab to safely and rapidly facilitate desensitization to multiple food allergens. Additional, larger studies will be needed to confirm and expand on these promising results.

Neither OIT nor omalizumab (trade name Xolair) currently is approved for the treatment of food allergy. (National Institutes of Health)

YOU MAY ALSO LIKE

An Aspirin A Day Keep Liver Cancer Away

A new study found that daily aspirin therapy was significantly associated with a reduced risk in hepatitis B related liver cancer.

Drink Coffee for a Longer Life

Drinking coffee was associated with lower risk of death due to heart disease, cancer, stroke, diabetes, and kidney disease.

Eat Chocolate for Steady Heartbea

Regular chocolate consumption may be linked to a lower risk of developing the heart rhythm irregularity atrial fibrillation, also known as heart flutter.

The Mechanism of Panic Attacks

Panic disorder is an anxiety disorder that afflicts 6 million American adults. It's characterized by unexpected, repeated episodes of intense fear. These can be accompanied by physical symptoms including chest pain, heart palpitations, shortness of breath, dizziness or abdominal distress. Panic disorder is also a risk factor for suicidal behavior.

Insomnia: Heart Attack, Stroke Risk

Insomnia is associated with increased risk of heart attack and stroke, according to a new research.

Omega-3s linked with lower risk of fatal heart attacks

Researchers found that blood levels of seafood- and plant-based omega-3 fatty acids were associated with a lower risk of dying from heart attacks.